EGFR and glioblastoma: Deletion of the proximal CTD (residues 958–1030, termed the ΔvIVb variant identified in glioblastoma multiforme patients), which removes the C1025 palmitoylation site, enhances EGFR signalling as measured by phosphorylation of the downstream MAPK effector Erk [29,32].